NCT02281409: Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors

NCT02281409
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Only triple negative breast cancer patients will be eligible for the expansion cohort
Exclusions: Evidence of central nervous system (CNS) metastases or symptomatic CNS metastases within 30 days prior to dosing
https://ClinicalTrials.gov/show/NCT02281409

Comments are closed.

Up ↑